Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01474538 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 122
- Enrollment target
NCT01474538 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 122 participants.
The verdict
NCT01474538, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 122 participants
- Enrollment target
Study Summary
This study will provide information on the use of insulin lispro and insulin aspart in insulin pumps in participants with type 2 diabetes.
Interventions
- DRUG Insulin Lispro
- DRUG Insulin Aspart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01474538
The ClinicalTrials.gov registry entry for NCT01474538 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin Lispro is the first listed.
NCT01474538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01474538 about?
NCT01474538 is a clinical study titled "Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy". This study will provide information on the use of insulin lispro and insulin aspart in insulin pumps in participants with type 2 diabetes.
What is the current status of trial NCT01474538?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 122 participants. The study started on 2011-12. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01474538?
The interventions under investigation include: Insulin Lispro (DRUG), Insulin Aspart (DRUG).
Who is sponsoring clinical trial NCT01474538?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.